All In Biotech

Drug Trial Radar · NCT07342491

Dasatinib for HIV-1 Reservoir Reduction

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

May 8, 2026

Primary completion

Apr 9, 2027

Study completion Sep 24, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or older who have been on ART for at least 48 months and have had a suppressed HIV-1 viral load for at least 36 months may be able to join. People will be randomly assigned to take dasatinib 100 mg by mouth once a day or a look-alike substance with no drug, called a placebo, for 12 weeks. Neither participants nor researchers will know who gets which (double-blind). The study team will do regular health checks and blood tests to track safety, tolerability, the HIV reservoir, and changes in immune cells. The study lasts 36 weeks total: 12 weeks of treatment and 24 weeks of follow-up, with clinic visits and possible phone calls. Fourteen people will take part; eight will get dasatinib and six will get placebo. Dasatinib may lower the HIV reservoir, but this is not guaranteed. All medicines can cause side effects, called adverse events (AE). The study team will watch closely and provide medical support. Joining is your choice, and you can leave at any time. If you leave, the team will talk with you about next steps for your care.

Conditions

  • HIV Infections

Interventions

  • DasatinibDrug

    will be administered as one 100 mg capsule (over-encapsulated tablet) orally once daily for 12 weeks

  • PlaceboOther

    Placebo for dasatinib will be administered as one placebo capsule (over-encapsulated tablet) orally once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in intact HIV-1 reservoir sizeTime frame: Baseline and week 12
  2. Number of Study treatment-related adverse eventsTime frame: From first dose through week 36

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Northwestern University CRS (Site # 2701)

    Chicago, Illinois · Recruiting

  • 2501, Case Clinical Research Site

    Cleveland, Ohio · Recruiting

  • 1401, University of Washington Positive Research CRS

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.